Frontiers in cellular and infection microbiology  ·  2025

ABSTRACT
Methicillin-resistant (MRSA) is a major clinical challenge due to its virulence and multidrug resistance. Antivirulence strategies targeting key pathogenic mechanisms without affecting bacterial viability provide a promising alternative to conventional antibiotics. The inhibitory effect of isoliquiritigenin (ISL) on sortase A (SrtA) was assessed using a fluorescence resonance energy transfer assay. Fluorescence quenching and molecular docking analyses were performed to elucidate the binding interaction between ISL and SrtA. Adhesion and biofilm formation were evaluated on fibrinogen- and fibronectin-coated surfaces, and bacterial growth was monitored to confirm non-bactericidal activity. The therapeutic efficacy of ISL was further examined in a murine pneumonia model through bacterial load quantification, histopathological analysis, and survival evaluation. ISL inhibited SrtA activity in a dose-dependent manner (IC = 13.34 µg/mL), disrupted adhesion and biofilm formation without affecting bacterial growth, and bound reversibly to key catalytic residues of SrtA. In vivo, ISL treatment significantly reduced pulmonary bacterial burden, alleviated tissue damage, and improved survival in infected mice. ISL effectively attenuates MRSA pathogenicity by targeting SrtA-mediated virulence rather than bacterial viability. These results highlight ISL as a promising antivirulence agent and a potential adjuvant for combating antibiotic-resistant S. aureus infections.

 Paraphrase     Questionfy     Wikify     Simplify     Summarize


year_of_publication2025
sourceFrontiers in cellular and infection microbiology

AI Reader
upload a document and start your AI-powered reading
AI Writer
you focus on what matters the most, we handle the rest
Daily Digest
get customized highlights of the latest research & news